NoticeThis is an independent non-profit initiative. We are not affiliated with the European Medicines Agency (EMA) or the official CTIS system. For the official EU Clinical Trials Information System, visit:
EMA Registry →
Patients with a histological diagnosis of mismatch- repair deficient high risk endometrial cancer (MMRd HREC; no POLEmut; all histology including carcinosarcoma), Stage IB/II with LVSI or stage IIIA-C. Patients are treated with curative intent, after surgery (hysterectomy and bilateralsalpingo-oophorectomy, with or without lymphadenectomy or sentinel node biopsy), without signs of residual disease or distant metastases.
1 total trials1 recruiting
Filter these 1 trials by phase, country, sponsor and more.